Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-25, Stock:NVS, The news for the past five days is as follows:
2019-02-15: NEWS1: U.S. Medicare plans to track CAR-T cancer therapy outcomes.NEWS2: Biogen Inc. -- Moody's announces completion of a periodic review of ratings of Biogen Inc..NEWS3: Medicare would cover CAR-T therapies under new CMS proposal.NEWS4: What Are the Key Growth Drivers for GlaxoSmithKline in 2019?.
2019-02-19: NEWS1: Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review.NEWS2: What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?.
2019-02-20: NEWS1: AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review.NEWS2: AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review.NEWS3: AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review.NEWS4: The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering.NEWS5: Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review.NEWS6: Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review.
2019-02-21: NEWS1: Biogen stock down 1.2% after downgrade by Stifel.
2019-02-22: NEWS1: Novartis gene therapy would be cost effective up to $900,000 -U.S. group.NEWS2: Novartis gene therapy is cost effective at up to $900,000 -U.S. group.NEWS3: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for February 25, 2019.NEWS4: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for February 25, 2019.

Answer: Rise